Expression of plasma miRNA-133a is significantly lower in Acute Coronary Syndrome (ACS) than in healthy/non-ACS subjects

Rachmawati, Ermin ORCID: https://orcid.org/0000-0003-1045-7066, Riskiyah, Riskiyah ORCID: https://orcid.org/0000-0001-7830-0298, Ahdi, Iwal Reza, Ismail, Mahrus ORCID: https://orcid.org/0000-0001-7606-3508, Sargowo, Djanggan ORCID: https://orcid.org/0000-0002-4558-130X, Saputra, Indra Wahyu ORCID: https://orcid.org/0009-0009-0114-6929, Handirosiyanto, Ikhwan ORCID: https://orcid.org/0009-0008-7133-8339, Hakim, Arief Rachman, Wardhani, Syanindita Puspa ORCID: https://orcid.org/0000-0003-0834-8514, Tarsadi, Tarsadi ORCID: https://orcid.org/0009-0006-3083-2942, Maulana, Syafiq ORCID: https://orcid.org/0009-0000-8341-111X and Puspitasari, Alvina (2024) Expression of plasma miRNA-133a is significantly lower in Acute Coronary Syndrome (ACS) than in healthy/non-ACS subjects. The Indonesian Biomedical Journal, 16 (5). pp. 464-472. ISSN 20853297

Text 21231.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB)

Abstract

BACKGROUND: The current biomarker diagnostic modality for acute coronary syndrome (ACS), cardiac troponin, has several limitations. Emerging studies showed that micro-RNA (miR)-133a was released from infarcted heart to circulation, yet the diagnostic value of miR-133a in ACS demonstrated a conflicting result. Therefore, this study was conducted to investigate the potency of plasma miR-133a as a biomarker candidate of ACS.

METHODS: This was a case-controlled study, involving ACS and control subjects. The sociodemographic and clinical characteristics were assessed through medical records. A final of 39 ACS and 31 control subjects (consist of healthy and non-ACS subjects) passed the selection procedure by demonstrating a high purity of RNA. miR-133a from ACS and control subjects were detected by quantitative polymerase chain reaction (qPCR). Expression of miR-133a was evaluated for sensitivity and specificity as an ACS biomarker diagnostic using the receiver operating characteristic (ROC) curve.

RESULTS: Plasma miR-133a expression was stably found in ACS subjects. The plasma miR-133a level was lower in ACS than in control subjects. miR-133a effectively distinguished ACS subjects from healthy subjects (AUC=0.911) and exhibited high diagnostic performance, with a sensitivity of 87.1% and specificity of 100% at a cut-off value of 44.035. In an extended model including both control subjects (healthy and non-ACS with comorbid conditions), miR-133a maintained diagnostic significance (AUC=0.874), showing sensitivity of 76.9% and specificity of 100% at a cut-off value of 11.69.

CONCLUSION: Plasma miR-133a is significantly lower and effectively distinguishes ACS patients from both healthy individuals and non-ACS individuals with comorbid, with a cut-off value of 11.69. Therefore, plasma miR-133a is suggested to be a good candidate for diagnostic biomarkers of ACS.

Item Type:	Journal Article
Keywords:	circulating miRNA; miRNA-133a; acute coronary syndrome; diagnostic biomarker
Subjects:	11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiorespiratory Medicine and Haematology > 110201 Cardiology (incl. Cardiovascular Diseases)
Divisions:	Faculty of Medical and Health Sciences > Department of Medical Education
Depositing User:	dr Ermin rachmawati
Date Deposited:	29 Nov 2024 13:12

Downloads

Origin of downloads

Actions (login required)

View Item